Table 2. Univariable and multivariable Cox regression model analyses of OS for nomogram.
| Characteristics | Univariable analysis | Multivariable analysis | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | ||
| Gender | 0.373 | ||||||
| Female | Reference | 1 | NA | ||||
| Male | 1.021 | 0.976–1.068 | 0.373 | ||||
| Age (years) | <0.001 | <0.001 | |||||
| ≤60 | Reference | 1 | Reference | 1 | |||
| 61–70 | 1.410 | 1.327–1.499 | <0.001 | 1.366 | 1.284–1.452 | <0.001 | |
| >70 | 3.011 | 2.859–3.171 | <0.001 | 2.565 | 2.427–2.710 | <0.001 | |
| Marital status | <0.001 | <0.001 | |||||
| Married | Reference | 1 | Reference | 1 | |||
| Unmarried/NOS | 1.478 | 1.414–1.544 | <0.001 | 1.203 | 1.150–1.258 | <0.001 | |
| Race | <0.001 | <0.001 | |||||
| White | Reference | 1 | Reference | 1 | |||
| Black | 1.264 | 1.174–1.361 | <0.001 | 1.256 | 1.165–1.354 | <0.001 | |
| Other/NOS | 0.869 | 0.804–0.940 | <0.001 | 0.904 | 0.836–0.977 | 0.011 | |
| Pathological grade | <0.001 | <0.001 | |||||
| I | Reference | 1 | Reference | 1 | |||
| II | 0.998 | 0.909–1.096 | 0.970 | 1.024 | 0.932–1.125 | 0.622 | |
| III | 1.412 | 1.273–1.567 | <0.001 | 1.338 | 1.204–1.486 | <0.001 | |
| IV | 1.709 | 1.398–2.087 | <0.001 | 1.471 | 1.203–1.799 | <0.001 | |
| Unknown | 1.149 | 1.023–1.291 | 0.019 | 1.007 | 0.896–1.132 | 0.907 | |
| Histological type | <0.001 | <0.001 | |||||
| Adenocarcinomas | Reference | 1 | Reference | 1 | |||
| MCC/SRCC | 1.344 | 1.249–1.445 | <0.001 | 1.262 | 1.171–1.359 | <0.001 | |
| T stage | <0.001 | <0.001 | |||||
| T1 | Reference | 1 | Reference | 1 | |||
| T2 | 1.024 | 0.866–1.211 | 0.781 | 1.015 | 0.857–1.201 | 0.864 | |
| T3 | 1.481 | 1.284–1.709 | <0.001 | 1.482 | 1.280–1.717 | <0.001 | |
| T4 | 2.786 | 2.391–3.246 | <0.001 | 2.469 | 2.109–2.890 | <0.001 | |
| N stage | <0.001 | <0.001 | |||||
| N0 | Reference | 1 | Reference | 1 | |||
| N1 | 0.924 | 0.880–0.971 | 0.002 | 1.262 | 1.197–1.330 | <0.001 | |
| N2 | 1.430 | 1.348–1.518 | <0.001 | 2.035 | 1.908–2.172 | <0.001 | |
| Surgery | <0.001 | <0.001 | |||||
| Yes | Reference | 1 | Reference | 1 | |||
| No | 2.938 | 2.764–3.122 | <0.001 | 2.024 | 1.839–2.227 | <0.001 | |
| Radiotherapy | <0.001 | <0.001 | |||||
| Neoradiotherapy | Reference | 1 | Reference | 1 | |||
| Radiotherapy* | 1.577 | 1.495–1.664 | <0.001 | 1.043 | 0.979–1.111 | 0.194 | |
| No/unknown | 2.046 | 1.942–2.157 | <0.001 | 1.220 | 1.132–1.315 | <0.001 | |
| Chemotherapy | <0.001 | <0.001 | |||||
| Yes | Reference | 1 | Reference | 1 | |||
| No/unknown | 2.030 | 1.936–2.129 | <0.001 | 1.448 | 1.351–1.551 | <0.001 | |
| RNE | <0.001 | <0.001 | |||||
| <3 | Reference | 1 | Reference | 1 | |||
| 3–5 | 0.556 | 0.508–0.610 | <0.001 | 0.856 | 0.771–0.951 | 0.004 | |
| 6–8 | 0.541 | 0.498–0.586 | <0.001 | 0.794 | 0.721–0.875 | <0.001 | |
| 9–11 | 0.503 | 0.465–0.544 | <0.001 | 0.730 | 0.663–0.803 | <0.001 | |
| ≥12 | 0.473 | 0.448–0.500 | <0.001 | 0.651 | 0.601–0.705 | <0.001 | |
| NOS | 0.738 | 0.604–0.903 | 0.003 | 0.965 | 0.786–1.183 | 0.730 | |
| Tumor size (cm) | <0.001 | <0.001 | |||||
| ≤5 | Reference | 1 | Reference | 1 | |||
| 5–10 | 1.281 | 1.214–1.351 | <0.001 | 1.113 | 1.053–1.175 | <0.001 | |
| >10 | 1.561 | 1.323–1.840 | <0.001 | 1.360 | 1.152–1.606 | <0.001 | |
| NOS | 1.158 | 1.092–1.227 | <0.001 | 1.051 | 0.988–1.117 | 0.117 | |
| CEA | <0.001 | <0.001 | |||||
| Negative | Reference | 1 | Reference | 1 | |||
| Positive | 1.543 | 1.457–1.633 | <0.001 | 1.354 | 1.278–1.435 | <0.001 | |
| NOS | 1.341 | 1.271–1.414 | <0.001 | 1.215 | 1.151–1.282 | <0.001 | |
*, not neoadjuvant. MCC, mucinous cell carcinoma; SRCC, signet ring cell carcinoma; RNE, regional nodes examined; NOS, not otherwise specified, NA, Unavailable.